158 related articles for article (PubMed ID: 9400998)
1. Induction of Mdm2 and enhancement of cell survival by bFGF.
Shaulian E; Resnitzky D; Shifman O; Blandino G; Amsterdam A; Yayon A; Oren M
Oncogene; 1997 Nov; 15(22):2717-25. PubMed ID: 9400998
[TBL] [Abstract][Full Text] [Related]
2. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase.
DeHaan RD; Yazlovitskaya EM; Persons DL
Cancer Chemother Pharmacol; 2001 Nov; 48(5):383-8. PubMed ID: 11761456
[TBL] [Abstract][Full Text] [Related]
3. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
4. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3.
Sharma K; Patel YC; Srikant CB
Mol Endocrinol; 1996 Dec; 10(12):1688-96. PubMed ID: 8961277
[TBL] [Abstract][Full Text] [Related]
5. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
[TBL] [Abstract][Full Text] [Related]
6. Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress.
Speidel D; Helmbold H; Deppert W
Oncogene; 2006 Feb; 25(6):940-53. PubMed ID: 16247471
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1.
Sato N; Mizumoto K; Maehara N; Kusumoto M; Nishio S; Urashima T; Ogawa T; Tanaka M
Anticancer Res; 2000; 20(2A):837-42. PubMed ID: 10810363
[TBL] [Abstract][Full Text] [Related]
8. Transcription abnormalities potentiate apoptosis of normal human fibroblasts.
Andera L; Wasylyk B
Mol Med; 1997 Dec; 3(12):852-63. PubMed ID: 9440118
[TBL] [Abstract][Full Text] [Related]
9. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells.
Hosokawa K; Aharoni D; Dantes A; Shaulian E; Schere-Levy C; Atzmon R; Kotsuji F; Oren M; Vlodavsky I; Amsterdam A
Endocrinology; 1998 Nov; 139(11):4688-700. PubMed ID: 9794481
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
Arriola EL; Lopez AR; Chresta CM
Oncogene; 1999 Jan; 18(4):1081-91. PubMed ID: 10023685
[TBL] [Abstract][Full Text] [Related]
12. A truncated isoform of the PP2A B56gamma regulatory subunit reduces irradiation-induced Mdm2 phosphorylation and could contribute to metastatic melanoma cell radioresistance.
Koma YI; Ito A; Watabe K; Kimura SH; Kitamura Y
Histol Histopathol; 2004 Apr; 19(2):391-400. PubMed ID: 15024700
[TBL] [Abstract][Full Text] [Related]
13. Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest.
Reinke V; Lozano G
Radiat Res; 1997 Aug; 148(2):115-22. PubMed ID: 9254729
[TBL] [Abstract][Full Text] [Related]
14. Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients.
Uberti D; Carsana T; Bernardi E; Rodella L; Grigolato P; Lanni C; Racchi M; Govoni S; Memo M
J Cell Sci; 2002 Aug; 115(Pt 15):3131-8. PubMed ID: 12118068
[TBL] [Abstract][Full Text] [Related]
15. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
Piovesan B; Pennell N; Berinstein NL
Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
[TBL] [Abstract][Full Text] [Related]
16. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
17. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells.
Yang HL; Dong YB; Elliott MJ; Liu TJ; Atienza C; Stilwell A; McMasters KM
Clin Cancer Res; 1999 Aug; 5(8):2242-50. PubMed ID: 10473112
[TBL] [Abstract][Full Text] [Related]
19. Rescue of mutant p53 transcription function by ellipticine.
Peng Y; Li C; Chen L; Sebti S; Chen J
Oncogene; 2003 Jul; 22(29):4478-87. PubMed ID: 12881704
[TBL] [Abstract][Full Text] [Related]
20. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.
Venot C; Maratrat M; Dureuil C; Conseiller E; Bracco L; Debussche L
EMBO J; 1998 Aug; 17(16):4668-79. PubMed ID: 9707426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
